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ABSTRACT
Increasing evidence supports that modifications in the mitochondrial content, oxidative phos-
phorylation (OXPHOS) activity, and cell metabolism influence the fate of stem cells. However,
the regulators involved in the crosstalk between mitochondria and stem cell fate remains poorly
characterized. Here, we identified a transcriptional regulatory axis, composed of transcription
factor 7-like 2 (TCF7L2) (a downstream effector of the Wnt/b-catenin pathway, repressed during
differentiation) and peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-
1a) (the master regulator of mitochondrial biogenesis, induced during differentiation), coupling
the loss of pluripotency and early commitment to differentiation, to the initiation of mitochon-
drial biogenesis and metabolic shift toward OXPHOS. PGC-1a induction during differentiation is
required for both mitochondrial biogenesis and commitment to the hepatocytic lineage, and
TCF7L2 repression is sufficient to increase PGC-1a expression, mitochondrial biogenesis and
OXPHOS activity. We further demonstrate that OXPHOS activity is required for the differentia-
tion toward the hepatocytic lineage, thus providing evidence that bi-directional interactions
control stem cell differentiation and mitochondrial abundance and activity. STEM CELLS
2017;35:2184–2197
SIGNIFICANCE STATEMENT
Mitochondria, which represent the major source of energy and power for the cells, are increas-
ingly recognized as major regulators of stem cells. In this study, we show that increasing the
content and activity of mitochondria is essential for stem cell differentiation into hepatocytes.
We identified a regulatory axis that couples the loss of pluripotency and commitment to differ-
entiation to the increase of mitochondria abundance and activity. In turn, mitochondrial activity
further supports the differentiation process. By better deciphering the interplay between mito-
chondria and stem cell differentiation, these findings could benefit the development of stem-
cell based therapeutics and regenerative medicine.
INTRODUCTION
Mitochondrial biogenesis and metabolism
recently emerged as critical modulators of stem-
ness properties and differentiation programs
[1]. Inhibiting mitochondrial biogenesis or
function prevents or disturbs the differentiation
of stem cells into multiple lineages [2] and
facilitates the reprogramming of somatic cells
into induced pluripotent stem cells [3]. These
data support a crucial role for mitochondria
and energy metabolism in the regulation of plu-
ripotency and differentiation-related pathways.
However, the molecular regulators involved in
this crosstalk between pluripotency and differ-
entiation on the one hand, and mitochondrial
biogenesis and metabolism on the other hand,
are still poorly characterized.
Conceptually, one can distinguish upstream
and downstream regulators of the interplay
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between mitochondrial biogenesis and stem cell differentiation.
The upstream regulators of the interplay could be defined as
the regulators involved in pluripotency and/or differentiation
pathways responsible for the control of mitochondrial biogene-
sis and metabolism. The downstream regulators on the other
hand, could be defined as the regulators of cell differentiation
that are activated following the induction of mitochondrial
biogenesis and metabolic shift. An example of upstream
regulator is the transcription factor hypoxia inducible factor 1
alpha (HIF-1a). In embryonic stem cells (ESCs), HIF-1a positively
regulates the expression of pluripotency genes while inhibiting
the expression of peroxisome proliferator-activated receptor
gamma coactivator-1 alpha (PGC-1a) [4], the master regulator of
mitochondrial biogenesis [5, 6]. Therefore, HIF-1a maintains
pluripotency while inhibiting mitochondrial biogenesis in ESCs
[4]. An example of downstream effectors are the mitochondrial
reactive oxygen species (ROS) produced during the adipogenic
differentiation of bone marrow mesenchymal stem cells
(BM-MSCs), which are required for the induction of the PPARc,
a master regulator of adipogenesis [7]. The question whether
those regulators are involved in the crosstalk between mito-
chondrial biogenesis and stem cell differentiation in different
models remains to be determined. It is likely that stem cell and
lineage-specificities exist, and that other molecular actors may
act together and/or independently of them in that process.
In this study, we investigated the crosstalk between mito-
chondrial biogenesis and the hepatocytic differentiation of BM-
MSCs. We found that the mitochondrial biogenesis and meta-
bolic shift toward oxidative phosphorylation (OXPHOS) occur
within the first days of hepatocytic differentiation and overlap
the loss of genes belonging to multipotency-related pathways.
Bioinformatics analyses of transcriptomics data collected during
the early steps of the differentiation process enabled us to iden-
tify multiple putative co-regulators of mitochondrial biogenesis
and cell differentiation, among which is PGC-1a. We found that
PGC-1a is required both for the induction of mitochondrial bio-
genesis and for the proper differentiation of BM-MSCs into
hepatocyte-like cells. To understand how PGC-1a expression is
induced during hepatocytic differentiation, we analyzed the
expression of predicted regulators of PGC-1a. Among them is
transcription factor 7-like 2 (TCF7L2), a downstream effector of
the Wnt/b-catenin signaling pathway. We evidenced that
TCF7L2 controls PGC-1a expression, mitochondrial biogenesis,
and OXPHOS activity in BM-MSCs, supporting the hypothesis
that TCF7L2 repression during hepatocytic differentiation
initiates PGC-1a induction, mitochondrial biogenesis, and meta-
bolic shift.
MATERIALS AND METHODS
Cell Culture and Differentiation
Cultures of human BM-MSCs were established as described pre-
viously [8] after informed consent from healthy donors and the
approval of the local ethics committee of the Jules Bordet Insti-
tute (Belgium). For all studies, at least three independent repli-
cates using cells isolated from different donors were performed.
All experiments were performed using cells from passages 4–7.
BM-MSCs were expanded in 1 g/l glucose Dulbecco’s Modi-
fied Eagle Medium supplemented with 1% penicillin–streptomy-
cin (PS) mixture (Life Technologies, Carlsbad, CA, now part of
Thermo Fisher (https://www.thermofisher.com/us/en/home/
brands/life-technologies.html)) and 10% fetal bovine serum (FBS,
PAA/GE Healthcare, Chicago, IL, http://www3.gehealthcare.com)
(“Exp” condition). Before the hepatocytic induction, BM-MSCs
were seeded on type-1 collagen (BD Biosciences, San Jose, CA,
http://www.bdbiosciences.com)-coated dishes and expanded till
95% confluency (“day 0”) (illustrated on Fig. 2). Hepatocytic
induction was carried out by incubating BM-MSCs in Iscove’s
Modified Dulbecco’s Medium (IMDM, Life Technologies) contain-
ing 1% PS mixture and supplemented with 20 ng/ml epidermal
growth factor (PeproTech, Rocky Hill, NJ, https://www.peprotech.
com) and 10 ng/ml basic-fibroblast growth factor (FGF-2, Pepro-
Tech) for 48 hours and then with 10 ng/ml FGF-2, 20 ng/ml hepa-
tocyte growth factor (PeproTech), 0.61 mg/ml nicotinamide
(Sigma-Aldrich, Saint-Louis, MO, https://www.sigmaaldrich.com),
and insulin–transferrin–selenium (ITS) mixture 1X (Life Technolo-
gies) for 10 days. Cells were then treated with a hepatocytic mat-
uration cocktail containing 20 ng/ml oncostatin M (PeproTech), 1
lM dexamethasone (Sigma-Aldrich) and ITS for 10 days. Undif-
ferentiated BM-MSCs were maintained in IMDM supplemented
with 1% FBS and 1% PS. For experiments involving OXPHOS
inhibitors, cells were differentiated or left undifferentiated in the
presence of 1 lM myxothiazol (Sigma-Aldrich), 5 lM antimycin A
(Sigma-Aldrich), 1 lM oligomycin (Sigma-Aldrich), or the corre-
sponding vehicles (1:2,000 dimethyl sulfoxide for myxothiazol
and 1:2,000 ethanol for antimycin A and oligomycin) throughout
the differentiation time course.
Lentiviral Vectors Production and Lentiviral
Transduction
Lentiviral vectors were produced in HEK293T cells following
transfection of envelope plasmid (pCMV-VSV-G, Addgene, Cam-
bridge, MA, https://www.addgene.org, #8454), packaging plas-
mid (psPAX2, Addgene #12260), and expression plasmid [pLKO.1
puro backbone containing the non mammalian shRNA control
(shNT, SHC002) or shRNA against PGC-1a (TRCN0000001165) or
TCF7L2 (TRCN0000061897) (Sigma-Aldrich)]. Lentiviral vectors
were titrated using the quantitative polymerase chain reaction
(qPCR) Lentivirus Titration kit (Applied Biological Material, Van-
couver, Canada, https://www.abmgood.com), according to the
manufacturer’s instructions. BM-MSCs at 60% confluency were
transduced in 25 cm2 flasks with 20 3 106 millions of lentiviral
particles in the presence of 60 lg/ml protamine sulphate
(Sigma-Aldrich). Transduced cells were selected with puromycin
1 lg/ml for 4–6 days and left without puromycin at least 2 days
before experiments.
Massive Analysis of cDNA Ends Analysis
Total RNA was isolated using the RNeasy Mini kit and Qiacube (Qia-
gen, Hilden, Germany, https://www.qiagen.com). For each condi-
tion, equal amounts of RNA isolated from five independent donor
cell batches were pooled and submitted to massive analysis of
cDNA ends (GenXPro, Frankfurt, Germany, http://genxpro.net).
Transcript per million normalization and tests for differential
expression of mapped reads were performed in the statistical pro-
gramming language R (www.rproject.org/) using the DEGexp func-
tion of the DEGseq package [9], after replacing the “0” counts by
the arbitrary “0.5” value. Data were deposited in NCBI’s Gene
Expression Omnibus [10] and are accessible through GEO Series
accession number GSE75184. Genes were considered as differen-
tially expressed if upregulated or downregulated with a p< .05 or
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with a p< .25 concomitantly with a |log2 fold-change|> 0.3785
(i.e., with fold changes >1.3 or< 0.769) (Supporting Information
Table S1). Since the p-value calculation relies on the number of
reads obtained for each gene, this procedure enabled us to take
into account genes with low mRNA levels, such as many transcrip-
tional regulators and co-regulators. Thus, genes considered as dif-
ferentially expressed in this study include (a) genes that are
statistically differentially expressed (p< .05), whatever the magni-
tude of the fold-change is and (b) genes that display a fold-change
greater than the indicated threshold (>1.3 or< 0.769), although
with a reduced statistical confidence (p< .25). Importantly, only
differentially expressed genes (DEGs) displaying a simultanenous
up- or downregulation in the three comparisons (differentiation vs.
expansion, differentiation vs. day 0, and differentiation vs. undiffer-
entiation within the same time point) were considered in our anal-
yses (Fig. 2). The requirement for a gene to be selected in the
three comparisons at the same time point enabled us to select the
changes due to the cell differentiation per se and not the expres-
sion changes due to the prolonged in vitro culture without serum
(comparisons vs. undifferentiated cells) or change in confluency
(comparisons vs. expansion condition) or basal medium (compari-
sons vs. expansion or vs. day 0).
Pathway and Gene Ontology Analyses
Data were analyzed using the QIAGEN’s Ingenuity Pathway
Analysis suite (IPA, QIAGEN, www.qiagen.com/ingenuity).
Gene ontology (GO)-TERMS annotations were analyzed using
DAVID Bioinformatics Resources [11].
Identification of Predicted Co-Regulators of
Mitochondrial Biogenesis and Stem Cell Commitment
to Differentiation
Biological process-, cell component-, and molecular function-
associated GO terms were retrieved for DEGs at day 5 of dif-
ferentiation. DEGs were then sorted based on their GO anno-
tations: one set was established with genes containing
annotations related to mitochondria (“Mitochondria dataset,”
Supporting Information Table S2), another one with genes
containing annotations related to (mesenchymal) stem cells or
differentiation (“Stem-diff dataset,” Supporting Information
Table S3). The “upstream analysis” function of IPA was used
to identify the putative regulators of these two lists of DEGs
(Supporting Information Tables S4, S5). This function, which
relies on a database containing the expected effects between
transcriptional regulators and their target genes, retrieves the
transcriptional regulators that are putatively involved in the
differential expression of a list of genes. It also predicts
whether these regulators are likely activated or inhibited,
based on the expression value of their targets.
Real-Time Reverse Transcriptase-qPCR Analysis
RNA extraction, cDNA synthesis, and qPCR were performed as
described previously [12] using the following primers: a1AT
(a-1-antitrypsin) F: GGGTCAACTGGGCATCACTAA R: CCCTTTCT
CGTCGATGGTCA; CPS1 (carbamoyl phosphate synthetase 1) F:
TCCTGATAGGCATCCAGCAATC R: AGGGACATTGTTGGCGTTGA;
PGC-1a (peroxisome proliferator-activated receptor gamma,
coactivator 1 alpha) F: TCCTTTCTCTCGCCCAACACGATCT R: GC
ATCCGACAGGACAAACAGTGGA; glutamine synthetase (GLUL) F:
CGCCGAGATGAGAAAGTTGT R: AAGCATGGCAGAGTGGGTAA;
DNA polymerase gamma (POLG) F: TGGCCTTGCAGATCACCAA
CCT R: TCCTTCCTGAGGCACCGGTCAA; POLG2 (DNA Polymerase
Gamma 2, Accessory Subunit) F: TCGACTCCAGTGGTGGAGAAA
R: TTCCTTTCCGGCCTTCTTCAT; POLRMT (RNA Polymerase,
Mitochondrial) F: GTGTACGGGGTCACGCGCTA R: CCGAGAACA
TCTCCTGTAGACTCTT; PPIE (Peptidyl-prolyl cis-trans isomerase
E) F: CCGCTCTTGACCCTGCATAT R: TCCAAGCAGACCCTGAGGAA;
TBX3 (T-box transcription factor 3) F: GTCGGGAAGGCGAATG
TTTC, R: ACGACAGTCATCAGCAGCTA; TCF7L2: F: CCTGGCACCGT
AGGACAAATC R: GAGGGAACCTGGACATGGAAGC; TDO2 (tryp-
tophan 2,3-dioxygenase) F: GAGGAACAGGTGGCTGAATTT R:GC
TCCCTGAAGTGCTCTGTA. All results were normalized to the
mRNA abundance of the housekeeping gene peptidyl-prolyl
cis-trans isomerase E (PPIE).
Determination of the Relative Abundance of
Mitochondrial DNA
The abundance of mitochondrial DNA (mtDNA) was quantified
as described previously [12].
Western Blot Analysis. Western blotting analyses were per-
formed as described previously [12], using the following primary
antibodies (Target, Manufacturer, Reference, Dilution factor): ATP
synthase a, Life Technologies, A21350, 1:1,000; ATP synthase b,
Life Technologies, A21351, 1:2,000; COX I (Cytochrome c oxidase,
subunit 1), Abcam, Cambridge, UK, http://www.abcam.com,
ab14705, 1:2000; COX II (Cytochrome c oxidase, subunit 2), Abcam,
ab110258, 1:2000; COX IV (Cytochrome c oxidase, subunit 3), Life
Technologies, A21348, 1:500; Histone 3, Cell Signaling Technology,
Danvers, MA, https://www.cellsignal.com, #4499, 1:5,000; PGC-1a
(peroxisome proliferator-activated receptor gamma, coactivator 1
alpha), Santa Cruz Biotechnology, Dallas, TX, https://www.scbt.
com, SC-13067, 1:500; TCF7L2, Cell Signaling Technology, #2569,
1:1,000; ubiquinol-cytochrome c reductase, complex III subunit VII
(UQCRQ), Proteintech, 14975–1-AP, 1:2,000.
Respiration Assays
The extracellular flux analyzer XF96 and the XF Cell Mito Stress
Test Kit (Seahorse Biosience, North Billerica, MA) were used to
perform metabolic profiling and assess mitochondrial function
[13]. The day before the assay, equal number of cells was seeded
in wells of a XF cell culture plate. A XF cell mito stress test (Sea-
horse Bioscience, part of Agilent, North Billerica, MA) was per-
formed according to the manufacturer’s instructions and using
the following chemical concentrations: 1 lM oligomycin, 0.5
lM carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone
(FCCP), 1 lM antimycin A, and 1 lM rotenone. Once oxygen
consumption rate (OCR) and extracellular acidification rate
(ECAR) measurements were performed, cells were lysed in 0.5 N
NaOH, and OCR and ECAR measurements were normalized to
the protein content of the well. Basal respiration was calculated
by substracting the non-mitochondrial oxygen consumption
[OCR following the addition of both antimycin A and rotenone
(mitochondrial complex III and I inhibitors, respectively)] to the
basal OCR. ATP coupling efficiency was calculated by substract-
ing the non-mitochondrial oxygen consumption from the OCR
following oligomycin addition (an ATP synthase inhibitor) and is
expressed as a percentage of the basal respiration. Spare respi-
ratory capacity was calculated by substracting the non-
mitochondrial oxygen consumption from the OCR following
FCCP (an uncoupling protonophore) addition and is expressed
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as a percentage of the basal respiration. For each condition and
each donor, 4–12 technical replicates were performed.
Immunofluorescence and Quantification of the
Mitochondrial Content per Cell
Cells were seeded on coverslips, fixed with 4% paraformaldehyde
for 20 minutes, permeabilized for 5 minutes with phosphate-
buffered saline (PBS)-1% Triton X-100, and then incubated for 2
hours with an anti-TOM20 antibody (Santa Cruz Biotechnology, SC-
11415, 1:200) (for mitochondria staining) and an anti-b-catenin
antibody (BD Transduction Laboratories, part of BD Bioscience, San
Jose, CA, http://www.bdbiosciences.com, BD610153, 1:100) (for
cytoplasm staining) diluted in PBS-1% bovine serum albumin (BSA).
Cells were then incubated for 1 hour with Alexa-labeled secondary
antibodies (Molecular Probes, Eugene, OR, now part of Thermo
Fischer, https://www.thermofisher.com/us/en/home/brands/
molecular-probes/key-molecular-probes-products.html) (1:1,000)
and observed by confocal microscopy (Leica Microsystems, Buffalo
Grove, IL, Dako (now Agilent Technologies, Santa Clara, CA, http://
www.agilent.com/)). The area occupied by the mitochondrial stain-
ing per cell was calculated using the ImageJ software.
Immunohistochemistry
Five micrometer thick human liver sections at different stages
were deparaffinized and rehydrated in graded alcohol series.
Endogenous peroxidase activity was blocked by incubation for 30
minutes in a 1% hydrogen peroxide methanol solution. Antigen
retrieval was performed by incubating the sections in citric acid
monohydrate solution (pH 9.0) at 988C for 35 minutes. Non-
specific immunostaining was prevented by 1 hour incubation in
PBS buffer containing either 5% (immunochemistry) or 10%
(immunofluorescence) BSA at room temperature. Slices were
incubated for 1 hour with polyclonal antihuman TCF7L2 (Abcam;
1:500), in 0.5% BSA at 378C. After washing with PBS-Tween-20
0.5% solution, immunostaining detection was visualized by Envi-
sion Dako anti-rabbit (Dako), using diaminobenzidine (Sigma) as
chromogenic substrate. The nuclei were counterstained using
Mayer’s hematoxylin for 10 minutes and mounted using Neo-
Entellan (Merck, Darmstadt, Germany, http://www.merck.com)
for microscopy analysis. The same protocol was used for immuno-
fluorescence staining with anti-TCF7L2 (Abcam; 1:500) and anti-
TOM20 (Santa Cruz Biotechnology, SC-11415, 1:200) except that
these primary antibodies were revealed by a 1 -hour incubation
with the corresponding Alexa-labeled secondary antibodies
(Molecular Probes) (1:1,000) before staining nuclei for 5 minutes
with 40,6-diamidino-2-phenylindole. Slides were mounted in fluo-
romount medium (Sigma).
Statistical Analyses
Depending on the data to compare, two-tailed paired t tests
(Figs. 1D, 5G–5J) or two-way paired analysis of variance tests
(Figs. 1A, 1B, 1C, 3, 4, 5C) were performed, assuming normal
distribution of data. In Figure 5G, data were log(2) transformed
to ensure homogeneity of variance. To identify the significantly
different groups, pairwise multiple comparisons using the
Student–Newman–Keuls method were performed (* or #, p< .05;
** or ##, p< .01; *** or ###, p< .001) (when used on a same
chart: *, comparisons of Diff vs. day 0; #, comparisons between
Diff and Undiff at a particular time point). All statistical analyses
were carried out using the SigmaPlot 12.5 software (Systat Soft-
ware, San Jose, CA, https://systatsoftware.com).
RESULTS
The Mitochondrial Biogenesis and Metabolic Shift
Toward OXPHOS Overlap the Decreased Expression of
Genes Involved in Pluripotency Pathways During the
Commitment of BM-MSCs to the Hepatocytic Lineage
We previously demonstrated a strong mitochondrial biogenesis,
characterized by an increase in the abundance of mitochondria,
mtDNA and several OXPHOS subunits, in a model of hepatocytic
differentiation of human BM-MSCs [12]. To get a deeper insight
into the mechanisms regulating this mitochondrial biogenesis,
we monitored these parameters over time. We evaluated the
abundance of mtDNA, of several OXPHOS subunits (the
UQCRQ), the subunits I, II, and IV of the cytochrome C oxidase
(COX I, COX II, and COX IV) and the subunits a and b of the ATP
synthase and the respiration rate throughout the hepatocytic
induction step (from day 0 to day 12 of the differentiation pro-
cess, lasting 22 days in total) (Fig. 1). A slight but significant
induction of mtDNA was detected since the 5th day of differen-
tiation (Fig. 1A). Similarly, several OXPHOS subunits were signifi-
cantly more abundant after 5 days of differentiation (Fig. 1B,
1C). This resulted, at the functional level, in a significantly
increased basal respiration, coupling efficiency (fraction of the
basal respiration that is used for ATP production) and spare
respiratory capacity (cell’s ability to increase substrates and
electron flux across the OXPHOS chain to respond to an
increased energy demand) of the OXPHOS system, as soon as 5
days of differentiation (Fig. 1D). In addition, the basal ECAR, an
undirect measurement of glycolysis, was lower in differentiated
BM-MSCs (Fig. 1D). These data support that the mitochondrial
biogenesis and metabolic shift toward OXPHOS occurred within
the first 5 days of hepatocytic differentiation.
To unveil the mechanisms regulating mitochondrial biogene-
sis during the differentiation of BM-MSCs into hepatocyte-like
cells, we performed transcriptomics analyses at early time
points of the differentiation process. Strikingly, analysis of the
10 most enriched pathways among genes upregulated after 5
days of differentiation revealed an enrichment of the “OXPHOS
pathway” (Fig. 1E, right panel). Indeed, 30 of 104 (29%) of the
OXPHOS subunits referenced in this pathway were upregulated
after 5 days of differentiation. These data support the notion
that the observed increased OXPHOS activity (Fig. 1D) is at least
partly explained by a broad induction of OXPHOS-related genes
at the transcript level. We also observed an induction of the
“Mitochondrial dysfunction pathway,” a pathway that includes
mitochondrial proteins frequently mutated or dysregulated in
mitochondrial diseases, including OXPHOS subunits, metabolic
enzymes (e.g., TCA cycle) and ROS detoxifying enzymes. This
observation supports the notion that many mitochondrial
genes—besides OXPHOS—are upregulated during differentia-
tion. The upregulation of ROS detoxifying enzymes has also
been reported during the osteogenic differentiation of MSC and
would protect the differentiating cells from the increased gener-
ation of ROS accompanying the switch toward OXPHOS metabo-
lism [14]. In agreement with the progressive acquisition of a
hepatic fate, an induction of metabolic pathways related to cho-
lesterol synthesis, a typical hepatic function, was also observed.
On the other hand, pathways involved in the regulation of stem-
ness and pluripotency, including the “human ESC pluripotency,”
“Wnt/b-catenin signaling,” and “transforming growth factor
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Figure 1. Mitochondrial biogenesis and metabolic shift toward oxidative phosphorylation (OXPHOS) occur early during the hepatocytic dif-
ferentiation. (A): Mitochondrial DNA abundance. (B): Abundance of several OXPHOS subunits analyzed by Western blot. (C): Quantification
of the signal intensity. (D): Metabolic profiling and assessment of the mitochondrial function of differentiated and undifferentiated cells at
day 5. (E): Top 10 enriched pathways among upregulated and downregulated genes after 5 days of differentiation, ranked according to
increasing p values of the enrichment. (A, C): Data are presented as the mean6 SEM, relative to cells in expansion. (D): Data are presented
as the mean6 SEM. (A–C) n 5 3, (D) n 5 4 independent experiments. * or #, p< .05; ** or ##, p< .01; *** or ###, p< .001; *, comparisons
versus day 0; #, comparisons between Diff and Undiff. Abbreviations: ECAR, extracellular acidification rate; EIF2, eukaryotic translation initia-
tion factor 2; FCCP, carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone; ILK, integrin linked kinase; mTOR, mammalian target of rapamy-
cin; OCR, oxygen consumption rate; TGF, transforming growth factor.
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beta (TGF-b) signaling” pathways, were strongly enriched
among the genes downregulated after 5 days of differentiation
(Fig. 1E, left panel). Thus, the induction of mitochondrial biogen-
esis overlaps the downregulation of genes belonging to path-
ways involved in the control of stem cell pluripotency, during
the early hepatocytic differentiation of BM-MSCs. Supporting
the loss of the mesenchymal phenotype and promotion of the
hepatic differentiation, a downregulation of genes involved in
the “hepatic fibrosis pathway “(that includes the TGF-b pathway
- an inhibitor of hepatocyte proliferation and differentiation
[15]- and downstream of it, expression of collagens) was
observed. Similarly, due to the important change in morphology
(cell elongation) observed during the first step of the differentia-
tion process, the “epithelial adherens junction pathway” (involv-
ing members of the TGF-b pathway, catenins, tubulins, and
actins) was also statistically downregulated.
Identification of Predicted Co-Regulators of
Mitochondrial Biogenesis and Stem Cell Commitment
to Differentiation
A lack of understanding currently resides in the mechanisms
connecting, on the one hand, the increase in mitochondrial
biogenesis and function and, on the other hand, the loss of
pluripotency and differentiation of stem cells. We hypothe-
sized that these two concomitant processes might be con-
trolled by common regulators. We thus investigated the
putative upstream regulators of DEGs (Supporting Information
Table S1) related to the mitochondria (Supporting Information
Table S2) and to stem cell pluripotency or differentiation (Sup-
porting Information Table S3), seeking to identify putative
common regulators of the two processes (Supporting Informa-
tion Table S4, S5, respectively) (the strategy developed to
identify those common regulators is detailed in the Material
and Method section and illustrated in Fig. 2).
Using IPA, 40 predicted co-regulators were identified, of
which 9 displayed after 3 and/or 5 days of differentiation a dif-
ferential expression consistent with their predicted activation
status (Table 1). Among them, HIF-1a is the candidate predicted
to be the most strongly repressed during differentiation, while
PGC-1a, predicted to be activated during differentiation, is the
candidate displaying the highest differential expression after 5
days of differentiation (Table 1). Noteworthy, the efficiency of
our bioinformatics approach in identifying co-regulators of
mitochondrial biogenesis and cell commitment to differentia-
tion is supported by the identification of HIF-1a as one of those
putative co-regulators. Indeed, in ESCs, HIF-1a positively regu-
lates pluripotency while inhibiting mitochondrial biogenesis and
function, through its binding to the promoter of pluripotency
genes and PGC-1a, resulting in transcriptional activation and
inhibition, respectively [4]. Since HIF-1a is not expressed at the
protein level in adult BM-MSCs (unpublished personal data and
[16]), we decided to further focus on PGC-1a. Importantly, PGC-
1a is reported to interact with multiple transcriptional regula-
tors also identified as putative co-regulators of mitochondrial
biogenesis and stem cell differentiation, including PPAR-a [17],
PPAR-g [18], the hepatocyte nuclear factor-4a (HNF-4a), and
the glucocorticoid receptor (GR or NR3C1) [19] (Table 1). These
observations suggest that PGC-1a might exert a broad effect on
the co-regulation of mitochondrial biogenesis and cell differen-
tiation. We thus investigated whether PGC-1a induction was
required for the hepatocytic differentiation of BM-MSCs and
the associated mitochondrial biogenesis.
Repressing PGC-1a Induction Partly Prevents
Mitochondrial Biogenesis and Hampers BM-MSC
Hepatocytic Differentiation
PGC-1a mRNA is strongly induced during hepatocytic differenti-
ation (Fig. 3A), resulting in a modest but significant increase in
the protein level (day 5 Diff vs. day 0: p 5 .032; day 12 Diff vs.
day 0: p 5 .002; day 22 Diff vs. day 0: p 5 .003) (Fig. 3D, 3E). To
test whether the 1.5-fold increase in PGC-1a abundance was
responsible for the increased mitochondrial biogenesis and
function, we used shRNA against PGC-1a. We repressed the
induction of PGC-1a mRNA by 54%, 52% and 64% after 5, 12
and 22 days of differentiation, respectively (Fig. 3A). At the pro-
tein level, we inhibited by 93%, 53% and 49% the
differentiation-induced increases in PGC-1a expression
observed at these respective time points (Fig. 3E). The fact that
we only partially repressed PGC-1a induction, without repres-
sing its abundance to lower levels than what is observed in
expanding stem cells (i.e., not lower than the fold change tres-
hold set to 1), allowed us to assess the requirement of PGC-1a
induction, specifically (rather than basal expression), for the
mitochondrial biogenesis and commitment to the hepatocytic
lineage.
The repression of PGC-1a led to a modest repression of
mtDNA relative abundance, mainly in undifferentiated cells and
cells differentiated for 5 days (Fig. 3B). To determine whether
other regulators were involved in the regulation of mtDNA
abundance, we analyzed the mRNA abundance of several major
regulators of mtDNA replication, including POLG, which enco-
des the catalytic core of the DNA polymerase g involved in
mtDNA replication; TFAM, a mitochondrial transcription factor
whose expression has been correlated with mtDNA abundance
[20] and of the mitochondrial RNA polymerase POLRMT, which
is involved in mtDNA replication by synthetizing an RNA primer
required for the initiation of mtDNA replication [21]. Modest
changes were observed in the expression of those regulators
during differentiation (Supporting Information Fig. S1). More-
over these changes were not consistent with the mtDNA induc-
tion profile observed during differentiation. More interestingly,
we found that the mRNA encoding the DNA polymerase g
accessory subunit POLG2, was increased 1.5- to twofolds during
the hepatocytic differentiation. Incidentally, we found that the
repression of PGC-1a led to a modest but significant repression
of POLG2 induction (Fig. 3B). Altogether, these data suggest
that PGC-1a regulates POLG2 expression, regulating itself
mtDNA replication. However, the partial inhibition of PGC-1a
induction - and hence, of POLG2 induction, only leads to minor
differences in mtDNA abundance.
In contrast, the repression of PGC-1a drastically prevented
the increase in mitochondrial content per cell observed by the
end of the hepatocytic induction step (Fig. 3C). The strong
impact of PGC-1a on mitochondrial abundance might be
related to its ability to co-activate several families of nuclear
transcription factors involved in mitochondrial biogenesis [5].
Similarly, PGC-1a repression was associated with a significant
decrease in the protein abundance of the subunits a and b of
the ATP synthase and of the subunit UQCRQ of the complex III
(Fig. 3D, 3E). Altogether, the partial repression of PGC-1a
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Figure 2. Strategy developed to identify common transcriptional regulators of gene expression changes related to stem cell differentiation
and mitochondria. Transcriptomics analyses were performed at early time-points of the differentiation process and differentially expressed
genes (DEGs) were identified (see Material and Method section for further details). Gene ontology (GO) terms were retrieved for DEGs at
day 5 of differentiation. DEGs were then sorted based on their GO annotations: one set was established with genes containing annotations
related to mitochondria (“Mitochondria dataset”), another one with genes containing annotations related to (mesenchymal) stem cells or
differentiation (“Stem-diff dataset”). The “upstream analysis” function of IPA was used to identify the putative regulators of these two lists of
DEGs. This function, which relies on a database containing the expected effects between transcriptional regulators and their target genes,
retrieves the transcriptional regulators that are putatively involved in the differential expression of a list of genes. It also predicts whether
these regulators are likely activated or inhibited, based on the expression value of their targets. The common regulators of the Stem-diff
dataset and mitochondria dataset were subsequently selected, and their expression profile at day 3 and/or 5 of differentiation was retrieved
(see Table 1). Abbreviations: DEG, differentially expressed gene; EGF, epidermal growth factor; FGF, fibroblast growth factor; GO, gene ontol-
ogy; HGF, hepatocyte growth factor; ITS, insulin–transferrin–selenium; MACE, massive analysis of cDNA ends; OSM, oncostatin M.
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Figure 3. Repressing peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1a) induction prevents mitochondrial
biogenesis and hampers hepatocytic differentiation. Cells were transduced with non-target control shRNA (shNT, white bars) or specific
shRNA against PGC-1a (shPGC-1a, grey bars) and submitted to hepatocytic differentiation. (A): PGC-1a mRNA abundance. (B): Mito-
chondrial DNA abundance and DNA polymerase gamma-2 mRNA abundance. (C): Immunofluorescence of the mitochondrial network,
visualized by a TOM20 immunostaining (red). Cells are counterstained using a b-catenin immunostaining (cyan blue). The mitochondrial
content per cell was determined by calculating the area, per cell, occupied by the mitochondrial network. Ten cells were analyzed per
condition and per experiment, n 5 3 independent experiments. Scale bar5 50 lm. (D): Abundance of several oxidative phosphorylation
subunits analyzed by Western blot. (E): Quantification of the Western blot signal intensity. (F): Morphology of cells at the end of the dif-
ferentiation process (day 22), observed by phase-contrast microscopy. Scale bar5 250 lm. (G): mRNA abundance of differentiation
markers. (A, B, E, G): Data are presented as the mean6 SEM, relative to untransduced cells in expansion. (C): Data are presented as the
mean6 SEM. (A, B, D, E, F, G): n 5 5 independent experiments. For clearness, only significant differences between transduction condi-
tions (shNT vs. shPGC-1a) were illustrated (*, p< .05; **, p< .01; ***, p< .001). Abbreviations: CPS1, carbamoyl phosphate synthetase
1; GLUL, glutamine synthetase; PGC-1a, peroxisome proliferator-activated receptor gamma coactivator-1 alpha; shNT, non-target control
shRNA; shPGC-1a, shRNA against PGC-1a; UQCRQ, ubiquinol-cytochrome c reductase, complex III subunit VII.
induction partly impaired the mitochondrial biogenesis
observed during the hepatocytic differentiation of BM-MSCs.
We next asked whether limiting the induction of PGC-1a
would also disturb the hepatocytic differentiation or not.
Strikingly, the acquisition of the typical hepatocyte-like polyg-
onal shape, normally observed by the end of the differentia-
tion process, was strongly hampered in cells transduced with
shRNA against PGC-1a (Fig. 3F). At the mRNA level, the induc-
tion of TBX3, a transcription factor expressed in hepatoblasts
[22] and induced during the early commitment to hepatocytic
differentiation, was completely abrogated in shRNA against
PGC-1a (shPGC-1a)-transduced cells (Fig. 3G). Moreover, a
delayed and reduced induction of the hepatocytic marker a-1-
antitrypsin (a1AT) was observed in shPGC-1a-transduced cells.
Similarly, a reduced induction of the hepatic/periportal gene
CPS1 and of the pericentral marker glutamine synthase (GLUL)
was observed by the end of the differentiation process (Fig.
3G). Altogether, these results support that PGC-1a is required
for the mitochondrial biogenesis, for the morphological matu-
ration into hepatocyte-like cells and for the acquisition of
hepatic gene expression of both periportal and perivenous
regions.
OXPHOS Activity Is Required for the Differentiation
into Hepatocyte-like Cells
PGC-1a co-activates several transcription factors involved in
liver development and hepatic gene expression, including
CCAAT/enhancer binding protein b [23], HNF-4a [19], the
forkhead box protein O1 [24], and the glucocorticoid receptor
[25]. Therefore, PGC-1a might contribute to hepatocytic dif-
ferentiation directly, by transactivating hepatic transcription
factors, and/or undirectly, by inducing mitochondrial biogene-
sis and function. To test the latter possibility, we differentiated
BM-MSCs in the presence of inhibitors of the mitochondrial
complex III (myxothiazol and antimycin A) and V (oligomycin).
Inhibiting OXPHOS activity prevented the acquisition of the
Figure 4. Inhibiting oxidative phosphorylation hampers hepatocytic differentiation. (A): Morphology of cells at the end of the differen-
tiation process (day 22), observed by phase-contrast microscopy. Scale bar5 250 lm. (B): mRNA abundance of differentiation markers
and peroxisome proliferator-activated receptor gamma coactivator-1 alpha. Data are presented as mean6 SEM (n5 4 independent
experiments) relative to untreated cells in expansion. For clearness, only significant differences between molecules and their vehicle
were illustrated (*, p< .05; **, p< .01; ***, p< .001). Abbreviations: CPS1, carbamoyl phosphate synthetase 1; DMSO, dimethyl sulfox-
ide; GLUL, glutamine synthetase; PGC-1a, peroxisome proliferator-activated receptor gamma coactivator-1 alpha.
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hepatocyte-like polygonal shape (Fig. 4A). Importantly, the
induction of the hepatocytic markers a1AT and tryptophan
2,3-dioxygenase (TDO2) is strongly reduced upon OXPHOS
inhibition (Fig. 4B). Myxothiazol treatment also inhibited the
induction of the periportal gene CPS1 and of the pericentral
marker GLUL (Fig. 4B). Importantly, the inhibitors did not
induce a strong ATP shortage (Supporting Information Fig. S2)
nor enhanced cell apoptosis (M Caruso, unpublished observa-
tions), supporting the requirement for mitochondrial activity,
specifically, for hepatocytic differentiation. Since the induction
of PGC-1a mRNA is enhanced in the presence of the different
OXPHOS inhibitors (Fig. 4B)—likely as a compensatory mecha-
nism for the decreased OXPHOS activity—these data support
that PGC-1a contributes to hepatocytic differentiation at least
partly through its ability to induce mitochondrial biogenesis
and function. Nonetheless, we did not observe any change in
TBX3 induction in the presence of the OXPHOS inhibitors
(unpublished observations), unlike upon PGC-1a repression
(Fig. 3G). These observations suggest that PGC-1a might in
addition stimulate hepatocytic differentiation independently
of OXPHOS.
The TCF7L2-PGC-1a Axis Links Mitochondrial
Biogenesis and Metabolic Shift to the Early
Commitment to Hepatocytic Differentiation
We next focused deeper on the upstream regulators of the
interplay between stem cell differentiation and mitochondrial
biogenesis. We hypothesized that the expression of PGC-1a
itself might be controlled by regulators of stem cell differenti-
ation. Using IPA, we retrieved the transcriptional regulators of
PGC-1a expression. We selected those that were differentially
expressed after 3 or 5 days of differentiation and which
expression changes were consistent with the induction of
PGC-1a, based on litterature data (Fig. 5A; Supporting Infor-
mation Table S6). TCF7L2 appeared as a strong candidate as it
is a downstream effector of the Wnt/b-catenin signaling path-
way [26] predicted to negatively affect PGC-1a expression
according to IPA. Interestingly, systems biology network analy-
ses revealed that TCF7L2 is functionally associated with the
stemness regulator SOX2 in human ESCs [27], emphasizing its
possible function as a molecular node connecting stem cell
loss of pluripotency to the initiation of mitochondrial biogene-
sis. In addition, the repression of Wnt/b-catenin signaling is
required for early liver specification [28]. Accordingly, we
observed a strong repression of TCF7L2 expression, particu-
larly at early time points of the hepatocytic differentiation
(Fig. 5B, 5C), as well as a global downregulation of genes
involved in the Wnt/b-catenin signaling pathway, after 5 days
of differentiation (Fig. 1E). Besides, we evidenced a progres-
sive downregulation of TCF7L2 expression during human liver
development (Fig. 5D, 5E). Thus, we hypothesized that the
downregulation of the Wnt/b-catenin signaling and of TCF7L2
expression during hepatic differentiation and maturation
might trigger PGC-1a induction, mitochondrial biogenesis and
metabolic shift. Supporting this hypothesis, we found that in
neonatal livers, hepatocytes with a high TCF7L2 staining in
the nuclei had a very limited mitochondrial network, while
those displaying the largest mitochondrial networks had no
detectable expression of TCF7L2 (Fig. 5F).
To test this hypothesis, we repressed TCF7L2 in expanding
BM-MSCs and assessed whether TCF7L2 repression would be
sufficient to induce mitochondrial biogenesis, independently of
the stimulation with differentiation cocktails. Using lentiviral-
mediated transduction of shRNA against TCF7L2, we repressed
TCF7L2 mRNA and protein abundance by 56% and 49%, respec-
tively (Fig. 5G–5I). In agreement with our hypothesis, TCF7L2
repression resulted in an increased abundance of PGC-1a tran-
script (Fig. 5G) and in a 17% increase in PGC-1a protein abun-
dance (Fig. 5H, 5I). Furthermore, the repression of TCF7L2
resulted in a significant increase in the abundance of several
OXPHOS subunits, including UQCRQ, COX I, COX II, COX IV, and
the subunit b of the ATP synthase (Fig. 5H, 5I) and in an
increased basal respiration rate (Fig. 5J). Altogether, TCF7L2
repression increases PGC-1a expression and OXPHOS activity in
BM-MSCs.
DISCUSSION
In this study, we postulated that mitochondrial biogenesis and
stem cell differentiation might be controlled by common tran-
scriptional regulators. We found that PGC-1a was necessary for
the induction of mitochondrial biogenesis and also for the acqui-
sition of hepatic gene expression during hepatic differentiation.
As previously mentioned, PGC-1a co-activates several
hepatic transcription factors, such as CCAAT/enhancer binding
protein b [23], HNF-4a [19], the forkhead box protein O1 [24],
and the glucocorticoid receptor [25], in addition to its ability to
co-activate mitochondrial transcriptional regulators such as the
estrogen-related receptor a (ERRa) or nuclear respiratory
factor-2 [5]. While we evidenced that OXPHOS activity is
required for the hepatocytic differentiation of BM-MSCs, further
studies are required to investigate the potential mitochondrial-
independent role of PGC-1a in that process. PGC-1a has been
demonstrated to regulate different loci through its interaction
with mitochondrial or hepatic transcription factors [23]. There-
fore, it would be interesting to investigate the loci and transcrip-
tion factors bound by PGC-1a at different time points of the
hepatocytic differentiation of BM-MSCs, to further elucidate its
involvement in the co-regulation of hepatocytic differentiation
and mitochondrial biogenesis. PGC-1a is also reported to regu-
late chondrogenesis by co-activating the transcription factor
SRY-related high mobility group-Box gene 9 (Sox9) in MSCs [30].
These data suggest that PGC-1a may co-regulate mitochondrial
biogenesis and stem cell differentiation into several lineages, by
co-activating different transcriptional regulators.
Although we restricted our studies to the transcriptional con-
trol of PGC-1a, it is worth mentioning that post-translational modi-
fications of PGC-1a affect its activity, including its ability to
coactivate different transcription factors. For example, the phos-
phorylation of PGC-1a downstream of the S6 kinase, activated
upon feeding in the liver, reduces the ability of PGC-1a to coacti-
vate HNF-4a, but not ERRa or PPARa [31]. This modification alters
the ability of PGC-1a to control the expression of neoglucogenic
but not mitochondrial genes [31]. Therefore, post-translational
modifications of PGC-1a likely control its ability to regulate mito-
chondrial biogenesis and stem cell differentiation toward different
lineages. This remains a complex area of research, given the high
number of post-translational modifications PGC-1a is subjected to
[32].
Upstream of PGC-1a, we found that TCF7L2 negatively con-
trols mitochondrial biogenesis and metabolic shift toward
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Figure 5. Transcription factor 7-like 2 (TCF7L2) is repressed during hepatocytic differentiation and its repression increases peroxisome
proliferator-activated receptor gamma coactivator-1 alpha (PGC-1a) expression, mitochondrial biogenesis, and function. (A): Transcrip-
tional regulators of PGC-1a (PPARGC1A) were retrieved using IPA. The regulators displaying a differential expression at day 3 and/or day
5 of differentiation (purple, downregulated; yellow, upregulated) consistent with the induction of PGC-1a are illustrated. (B): Abundance
of TCF7L2 analyzed by Western blot. (C): Quantification of the Western blot signal intensity. Data are expressed relative to expanding
cells and presented as mean6 SEM (n 5 6 independent experiments). (D): TCF7L2 expression was visualized by immunohistochemistry
on sections from two independent fetal livers and adult livers. (E): TCF7L2 expression was visualized by immunofluorescence on sections
from fetal, neonatal, and adult livers. Nuclei were stained with 40,6-diamidino-2-phenylindole (DAPI). (F): TCF7L2 and TOM20 were ana-
lyzed by immunofluorescence on sections from neonatal livers. Nuclei were stained with DAPI. Arrows indicate cells with large mito-
chondrial networks and no expression of TCF7L2. (G–J): Cells were transduced with non-target control shRNA (white bars) or specific
shRNA against TCF7L2 (shTCF7L2) (grey bars). (G): mRNA abundance of TCF7L2 and PGC-1a. (H, I): Abundance of proteins analyzed by
Western blot and quantification of the signal intensity. (J): Basal respiration determined by an extracellular flux analyzer. (G–J): Data are
presented as mean6 SEM of n 5 7 independent experiments. * or #, p< .05; ** or ##, p< .01; *** or ###, p< .001. For (C), *, compar-
isons versus day 0; #, comparisons between Diff and Undiff. Abbreviations: CV, central vein; OCR, oxygen consumption rate; PGC-1a,
peroxisome proliferator-activated receptor gamma coactivator-1 alpha; PV, portal vein; shNT, non-target control shRNA.
OXPHOS. TCF7L2 is strongly repressed during the first days of
the hepatocytic differentiation process, suggesting that its
repression would be particularly important to initiate the induc-
tion of PGC-1a expression. PGC-1a is known to control its own
expression in an auto-regulated manner [5], which may explain
its sustained induction throughout the differentiation process,
despite a weaker repression of TCF7L2 at later stages. Interest-
ingly, previous data support a role for the downregulation of the
Wnt/ß-catenin signaling pathway both in vivo [28], for the early
stages of liver development and in vitro, for the hepatocytic dif-
ferentiation of MSCs [33]. In umbilical cord blood-derived MSCs,
the downregulation of FRIZZLED 8, a key component of the
Wnt/b-catenin signaling pathway, was demonstrated to reduce
TCF7L2 expression and favor the expression of several hepato-
cytic markers, including albumin, C/EBPa, and CYP1A1/2 [33].
While it was previously unclear how the downregulation of
Wnt/b-catenin and TCF7L2 might contribute to the differentia-
tion of hepatocytes, our data support the hypothesis that the
TCF7L2-mediated control of PGC-1a expression, mitochondrial
biogenesis and activity, are at least partly involved. Importantly,
the activation of canonical Wnt signaling was reported to inhibit
PGC-1a expression and the differentiation of brown adipocytes
[34], suggesting that the Wnt/b-catenin-PGC-1a axis might con-
nect mitochondrial biogenesis with stem cell differentiation into
different lineages.
CONCLUSION
Although mitochondria and metabolism are now considered as
critical regulators of the pluripotency and differentiation of stem
cells [1, 29], the molecular mechanisms regulating the crosstalk
between these two processes remain elusive. In this study, we
provided data supporting that TCF7L2 repression upon commit-
ment to hepatocytic differentiation de-represses mitochondrial
biogenesis and triggers the differentiation-associated metabolic
shift toward OXPHOS, by inducing PGC-1a expression. In turn,
PGC-1a and OXPHOS activity further contribute to the differentia-
tion to the hepatocytic lineage, by regulating the expression of
hepatocytic genes and supporting the morphological maturation
associated with the differentiation process.
Importantly, better deciphering the interplay between
mitochondria and stem cell differentiation should improve our
ability to manipulate stem cells in vitro, which is of great
interest for the development and optimization of stem cell-
based therapeutics. In addition, since mitochondria regulate
the pluripotency and function of stem cells, which are com-
promised upon aging and diseases, understanding this inter-
play might also lead to the development of regenerative
medicine and novel anti-aging therapies.
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